CMPS | COMPASS Pathways plc Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	4.03 - 4.37
52 Week Range	3.17 - 12.75
Beta	1.98
Implied Volatility	216.18%
IV Rank	72.83%
Day's Volume	1,409,247
Average Volume	1,144,730
Shares Outstanding	65,911,498
Market Cap	274,850,947
Sector	Healthcare
Industry	Medical - Care Facilities
IPO Date	2020-09-18

Valuation
Profitability
Growth
Health
P/E Ratio	-1.91
Forward P/E Ratio	N/A
EPS	-2.18
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	186
Country	UK
Website	CMPS

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

CMPS's peers: INNV, AGL, USPH, EHAB, ENSG, CCRN, AMED, ACHC, ADUS, SGRY, PNTG, NHC, DVA, FSNUY

*Chart delayed

Analyzing fundamentals for CMPS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see CMPS Fundamentals page.

Watching at CMPS technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on CMPS Technicals page.